TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number cases with pulmonary hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants requiring vasopressors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change in Tinnitus Functional Index (TFI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of acute-dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Changes between baseline laboratory assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic response rate (R0 resection)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate to mirdametinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Report of Acupressure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiovascular Related Death
Endpoint domain: Mortality/survival
Primary endpoint: Equilibrium Score on Sensory Organization Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of neointima
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of telephone calls
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Clinical frailty score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EuroQol 5-Dimension 5-Level (EQ-5D-5L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Maximum Power in Wingate Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Total Work in Wingate Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in VO2max measured with cycloergometer cardiopulmonary exercise testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in forced volume vital capacity (FVC) measured with spirometry test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in on-ice performance measured with time trial effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of Treatment Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Resilience measured by the Child Youth Resilience Measure (CYRM)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Antibody-mediated Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants with clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of endocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of women completing cervical cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month progression-free survival percentage (PFS%)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: UES peak pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in knee functional disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Radiological fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: RV-LV-Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sdc-1 perioperative changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving complete closure of target ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adverse Events (AEs) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Completion of the procedure without conversion
Endpoint domain: Adverse events/effects
Primary endpoint: Protocol Adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in interstitial glucose time in range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perception of Aggression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Violence Checklist
Endpoint domain: Adverse events/effects
Primary endpoint: Signs of ongoing pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Concentration of total copper in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: heart rate between 60 and 90 /min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: respiratory rate less than 20/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: O2 saturation greater than 94% without oxygen supply
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Bimanual Assessment Measure (BAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without disability at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients with functional independence at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Modified ODI for disability (Urdu version)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Standardized uptake value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Muscle Endurance Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Autonomic Nervous System Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modified Star Excursion Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III in OFF phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Postural Habits and Awareness Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quick Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Difference in craving between drug and placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in tobacco withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cigarettes smoked ad lib
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Circulating Plasma Levels of Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Kunming Locomotor Scale (KLS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: White Matter Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absolute change in LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative (percentage) change in LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fertility-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Immunogenicity of the candidate vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Samples with Matching Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pression algometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ratio of actual treatment time to predicted treatment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in Troponin-I values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Respondence rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: NOSE questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Exercise level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of a composite cardiovascular endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quadriceps CSA MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Persistent clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and intensity of chronic pain after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detectable TFV levels in hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of EDP-235
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of EDP-235
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in microbiota in diseased vs. non-diseased lung segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Association of specific microbial taxa with elevated SCFAs and impaired host inflammation and tissue repair biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of treatment on the lung microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viremia levels after second vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bloating on Visual Analog Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in bowel movements in a bowel-movement diary
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of discrepancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of radiation proctitis
Endpoint domain: Adverse events/effects
Primary endpoint: 1-year Progression free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Diaphragmatic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Keratinized gingival thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratinized gingival width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of the study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Uptake of 89Zr-girentuximab within individual tumor deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: absolute neutrophil cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: interleukin-8 levels in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Academic high school attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: bacterial composition of dental biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gingival enlargement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ROP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of abnormal retinal microanatomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Severity of abnormal retinal microanatomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Retinal thickness at the fovea and surrounding optic nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Myopia changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parturient satisfaction with analgesia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ability to recruit the needed sample size
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in Assessment of Melasma Color Intensity Using Chroma Meter CR 400
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Improvement From Baseline in Quality of Life as Assessed by the Melasma Quality of Life Scale (MELASQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the concentration-time curve (AUC) of total ketones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum observed concentration (Cmax) of total ketones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time of maximum concentration (Tmax) of total ketones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of treatment emergent adverse event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) due to TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Spatial correlation of PET uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Strength of correlation between CD8+ cells and T cell activation features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rates of blood transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acceptability of the single session intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of the single session intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) of Total Apramycin in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Total Apramycin in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Elimination Half-Life (t1/2) of Total Apramycin in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left bronchial mucosal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fear-avoidance beliefs
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Adolescent Adult Sensory Profile score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Urodynamics Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Extended Disability Status Scale (EDSS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overactive Bladder Questionnaire-V8 (OAB-V8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants with Serious Adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Clinically Significant Changes in Laboratory Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dapivirine plasma pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with clinically significant laboratory test abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with clinically significant vital signs abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung-elastance changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in PROMIS Pain Interference Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Levels of plasma cannabinoid and cannabinoid metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reverse Corsi Task (Change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Go/NoGo Task (Change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrocardiograph (Change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Electrodermal Activity (Change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive and Negative Affect Schedule - Expanded Form (Change)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fatigue State Questionnaire (Change)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Overall Burden of cGVHD diagnosis and severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Annualized rate of medical facility VOEs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with protocol specified Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Self-perceptions of facial appearance and well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean duration of seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change from baseline in hand modified Total Lesion Symptom Score (mTLSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR) and/or partial response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Evoked Potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sinus airflow and particle deposition rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of MUST MINI system
Endpoint domain: Adverse events/effects
Primary endpoint: Predictive value for cardiovascular/hypertensive disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of grade ≥3 treatment-related skin and soft tissue toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Psychological Well-Being Scale for Older Adults
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Life Satisfaction Scale for Older Adults
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the plasma concentration - time curve of esketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Boston Carpal Tunnel Syndrome Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Undesirable effects
Endpoint domain: Adverse events/effects
Primary endpoint: LVOT gradients post-myectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low-density lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High-density lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: integrated gastric acidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time of first acute exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of second acute exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-level sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic Response Based on SES-CD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stillbirth or major morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Fetal weight measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients discontinuing therapy due to toxicity or intolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Clearance (CL) of unbound ceftriaxone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution (VD) of unbound ceftriaxone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penetration rate of unbound ceftriaxone from blood to ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination rate of unbound ceftriaxone from ascites by paracentesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete resolution of all treated wart(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes